Építés alatt – nem éles oldal
Belépés
LeállítvaNo phase

Safety and Effectiveness of the Hydrus Microstent

Megadott ok: Enrollment

Key facts

Where
Bentonville, Fraser, Kenosha, Mason és Zephyrhills, Egyesült ÁllamokSee the 5 sites

Where in Egyesült Államok

  • Vold Vision PLLCBentonville, Egyesült ÁllamokNo longer taking part
  • Fraser Eye Care CenterFraser, Egyesült ÁllamokNo longer taking part
  • Eye Centers of Racine and KenoshaKenosha, Egyesült ÁllamokNo longer taking part
  • Cincinnati Eye / Apex EyeMason, Egyesült ÁllamokNo longer taking part
  • The Eye Clinic of FloridaZephyrhills, Egyesült ÁllamokNo longer taking part

Trial details

Who runs it
Alcon Research
Trial code
NCT05198297
Record updated
2025. január 15.
Original description
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on topical hypotensive medication and prior to incisional glaucoma surgery.Read full original descriptionShow less

The Hydrus® Microstent for Intraocular Pressure (IOP) Reduction in Mild to Moderate Open-Angle Glaucoma

The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on topical hypotensive medication and prior to incisional glaucoma surgery.

Inclusion: Early or moderate glaucomatous optic nerve damage; Uncomplicated cataract surgery with well centered posterior chamber IOL greater than or equal to 365 days prior to the screening visit; Inadequately controlled IOP; Shaffer angle grade III-IV in all four quadrants; Age appropriate minimum central endothelial cell density; Other protocol-defined inclusion criteria may apply.

Exclusion: Requires oral hypotensive medications; Prior glaucoma surgery; Diagnosis of acute angle closure, chronic angle closure, or congenital, malignant, or developmental glaucoma; Ocular hypertension; Shallow or flat anterior chamber; Other protocol-defined exclusion criteria may apply.

ClinicalTrials.gov NCT05198297